Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD5305 + Darolutamide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5305 | AZD 5305|AZD-5305 | PARP-1 Inhibitor 8 | AZD5305 inhibits PARP1, potentially inhibiting cell growth and inducing tumor regression (PMID: 35929986). | |
Darolutamide | Nubeqa | BAY1841788|ODM-201 | Hormone - Anti-androgens 48 | Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer, and in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06120491 | Phase III | AZD5305 + Enzalutamide Abiraterone + AZD5305 AZD5305 + Darolutamide Darolutamide Enzalutamide Abiraterone | AZD5305 vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 15 |
NCT05938270 | Phase I | Darolutamide AZD5305 + Darolutamide AZD5305 | A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN) | Recruiting | USA | NLD | GBR | ESP | CAN | AUS | 0 |
NCT05367440 | Phase Ib/II | AZD5305 + Darolutamide Abiraterone + AZD5305 AZD5305 + Enzalutamide | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) | Recruiting | USA | ITA | GBR | AUS | 0 |